Sat 17 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia | Novartis Saudi Ltd | Ongoing | kisqaLi (ribociclib) | 2 | CLEE011ASA | King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure | Astrazeneca | Ongoing | D6972C00002 | 3 | D6972C00002 | King Faisal Specialist Hospital and Research Center (Riyadh) ,King Fahad Specialist Hospital (Dammam) ,King Fahad Medical City (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Riyadh) |
| Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly | Novo Nordisk | Ongoing | Semaglutide | 3 | NN9536-7752 | King Khalid University Hospital (Riyadh) ,King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia | Moderna | Ongoing | mRNA-3927 | 1/2 | mRNA-3927-P101 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| King Abdullah International Medical Research Center’s (KAIMRC) | Ongoing | Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine | 2 | RJ19/119/J | King Abdullah Medical Complex (Jeddah) | |
| King Faisal Specialist Hospital and Research Center (Jeddah) | Ongoing | Insulin | 3 | 2023-45 | King Faisal Specialist Hospital and Research Center (Jeddah) | |
| Inozyme Pharma, Inc | Ongoing | INZ701 | 3 | INZ701-106 | King Faisal Specialist Hospital and Research Center (Riyadh) | |
| AbbVie | Ongoing | Risankizumab | 3 | M23-784 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) | |
| Astrazeneca | Ongoing | Anifrolumab | 4 | TMP-0010230 | Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh) | |
| King Faisal Specialist Hospital and Research Center (Riyadh) | Ongoing | Semaglutide | 3 | 2241130 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.